November 2021
Additional drugs require prior authorization for URMBT members with Blue Cross non‑Medicare plans
We’re adding prior authorization requirements through AIM Specialty Health® for the following drugs covered under the medical benefit for UAW Retiree Medical Benefits Trust members with Blue Cross Blue Shield of Michigan non-Medicare plans.
These drugs will require prior authorization for dates of service on or after Dec. 3:
- Darzalex Faspro™ (daratumumab and hyaluronidase-fihj), HCPCS code J9144
- Polivy™ (polatuzumab vedotin-piiq), HCPCS code J9309
- Trodelvy™ (sacituzumab govitecan-hziy), HCPCS code J9317
These drugs will require prior authorization for dates of service on or after Jan. 3, 2022:
- Enhertu® (fam-trastuzumab deruxtecan-nxki), HCPCS code J9358
- Jelmyto® (mitomycin), HCPCS code J9281
- Lumoxiti® (moxetumomab pasudotox-tdfk), HCPCS code J9313
- Padcev® (enfortumab vedotin-ejfv), HCPCS code J9177
- Phesgo™ (pertuzumab, trastuzumab and hyaluronidase–zzxf), HCPCS code J9316
- Sarclisa® (isatuximab-irfc), HCPCS code J9227
- Zepzelca™ (lurbinectedin), HCPCS code J9223
Prior authorization requirements apply when these drugs are administered in an outpatient setting.
This requirement doesn’t apply to the UAW Retiree Health Care Trust (group number 70605) or the UAW International Union (group number 71714).
How to submit authorization requests
Submit prior authorization requests to AIM using one of the following methods:
Additional information
Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.
For additional information on requirements related to drugs covered under the medical benefit for UAW Retiree Medical Benefits Trust members with Blue Cross non-Medicare plans, see:
We’ll update the appropriate drug lists to reflect the information in this article before the effective date.
Accredo manages prior authorization requests for additional medical benefit drugs.
**Blue Cross Blue Shield of Michigan doesn’t own or control this website. |